K. Lisowska: For hematooncology patients, access to innovative therapies means "to be or not to be."

At the end of March, the Agency for Health Technology Assessment and Tarification published a list of highly innovative drug technologies (TLIs). It includes only 8 of the 33 technologies considered under the process described by the provisions of the Medical Fund Law. Only two anti-cancer therapies are on the list, and none for the treatment of blood cancers is included in the document. In that case, are no new therapies worthy of funding?

I am unable to understand why this happened. The Medical Fund was a promise of improvement for all oncology patients and was supposed to provide access to modern treatment. Meanwhile, it turned out, none of the molecular indications in hematooncology appeared on the list. As a result, our pati...